泌尿外科指南

订阅

MedSci主页 / 所有栏目 / 泌尿外科指南

2021 AUA指南：良性前列腺增生所致下尿路症状的管理-第Ⅰ部分：初步检查和药物治疗

2021-08-13 美国泌尿外科学会 Journal of Urology

泌尿外科良性前列腺增生

2021年8月，美国泌尿外科学会(AUA)发布了良性前列腺增生所致下尿路症状的管理指南，本文为该指南的第1部分，内容涉及初步检查和药物治疗。

中文标题：

2021 AUA指南：良性前列腺增生所致下尿路症状的管理-第Ⅰ部分：初步检查和药物治疗

英文标题：

Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management

发布机构：

美国泌尿外科学会

发布日期：

2021-08-13

简要介绍：

2021年8月，美国泌尿外科学会(AUA)发布了良性前列腺增生所致下尿路症状的管理指南，本文为该指南的第1部分，内容涉及初步检查和药物治疗。良性前列腺增生是一种组织学诊断，本文主要针对良性前列腺增生所致下尿路症状的管理提供循证指导，提出了19项与评估、检查和药物指南相关的指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 AUA指南：良性前列腺增生所致下尿路症状的管理-第Ⅰ部分：初步检查和药物治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a76061c0022ea2d1, title=2021 AUA指南：良性前列腺增生所致下尿路症状的管理-第Ⅰ部分：初步检查和药物治疗, enTitle=Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management, guiderFrom=Journal of Urology, authorId=0, author=, summary=2021年8月，美国泌尿外科学会(AUA)发布了良性前列腺增生所致下尿路症状的管理指南，本文为该指南的第1部分，内容涉及初步检查和药物治疗。, cover=https://img.medsci.cn/20211129/1638150997971_1608702.png, journalId=0, articlesId=null, associationId=87, associationName=美国泌尿外科学会, associationIntro=AUA成立于1902年， 是全球泌尿外科领域最具影响力的学术组织之一，在全球化的背景下，联合世界各地的泌尿专家促进了学术界的最新科学研究以及临床治疗，确保世界各地的患者都能接收到最高水平的治疗。 出版包括Journal of Urology在内的多种重要刊物。, copyright=0, guiderPublishedTime=Fri Aug 13 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年8月，美国泌尿外科学会(AUA)发布了良性前列腺增生所致下尿路症状的管理指南，本文为该指南的第1部分，内容涉及初步检查和药物治疗。良性前列腺增生是一种组织学诊断，本文主要针对良性前列腺增生所致下尿路症状的管理提供循证指导，提出了19项与评估、检查和药物指南相关的指导建议。</span></p>, tagList=[TagDto(tagId=300, tagName=泌尿外科), TagDto(tagId=34441, tagName=良性前列腺增生)], categoryList=[CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=34441, guiderKeyword=良性前列腺增生, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1835, appHits=108, showAppHits=0, pcHits=486, showPcHits=1718, likes=0, shares=15, comments=6, approvalStatus=1, publishedTime=Mon Nov 29 10:04:25 CST 2021, publishedTimeString=2021-08-13, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Mon Nov 29 10:00:39 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Thu Jan 04 12:28:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 AUA指南：良性前列腺增生所致下尿路症状的管理-第Ⅰ部分：初步检查和药物治疗.pdf)])
2021 AUA指南：良性前列腺增生所致下尿路症状的管理-第Ⅰ部分：初步检查和药物治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1198736, encodeId=b4cb1198e3672, content=一起来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1b925502269, createdName=佐佐佑佑, createdTime=Wed Mar 02 15:23:24 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079329, encodeId=8b7710e932948, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Sun Dec 12 22:03:41 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078067, encodeId=eb2610e8067df, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211130/4e30917e949f447faa863c62dade7ada/cda894f8e2f84535929f76cc0eb72509.jpg, createdBy=4a382568287, createdName=L-李, createdTime=Wed Dec 08 11:23:51 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075306, encodeId=d54e10e53061c, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:36 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2022-03-02 佐佐佑佑

    一起来学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1198736, encodeId=b4cb1198e3672, content=一起来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1b925502269, createdName=佐佐佑佑, createdTime=Wed Mar 02 15:23:24 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079329, encodeId=8b7710e932948, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Sun Dec 12 22:03:41 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078067, encodeId=eb2610e8067df, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211130/4e30917e949f447faa863c62dade7ada/cda894f8e2f84535929f76cc0eb72509.jpg, createdBy=4a382568287, createdName=L-李, createdTime=Wed Dec 08 11:23:51 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075306, encodeId=d54e10e53061c, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:36 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-12 ms7000000920508122

    不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1198736, encodeId=b4cb1198e3672, content=一起来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1b925502269, createdName=佐佐佑佑, createdTime=Wed Mar 02 15:23:24 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079329, encodeId=8b7710e932948, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Sun Dec 12 22:03:41 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078067, encodeId=eb2610e8067df, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211130/4e30917e949f447faa863c62dade7ada/cda894f8e2f84535929f76cc0eb72509.jpg, createdBy=4a382568287, createdName=L-李, createdTime=Wed Dec 08 11:23:51 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075306, encodeId=d54e10e53061c, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:36 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-08 L-李

    不错不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1198736, encodeId=b4cb1198e3672, content=一起来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1b925502269, createdName=佐佐佑佑, createdTime=Wed Mar 02 15:23:24 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079329, encodeId=8b7710e932948, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e646399295, createdName=ms7000000920508122, createdTime=Sun Dec 12 22:03:41 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078067, encodeId=eb2610e8067df, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211130/4e30917e949f447faa863c62dade7ada/cda894f8e2f84535929f76cc0eb72509.jpg, createdBy=4a382568287, createdName=L-李, createdTime=Wed Dec 08 11:23:51 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075306, encodeId=d54e10e53061c, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:36 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-11-30 微探

    学习学习

    0

相关指南

2021 AUA/SUFU指南：成人神经源性下尿路功能障碍的治疗和随访

美国泌尿外科学会(AUA,American Urological Association) · 2021-11-20

2021 AUA/SUFU指南：成人神经源性下尿路功能障碍的诊断和评估

美国泌尿外科学会(AUA,American Urological Association) · 2021-11-20

泌尿外科腹腔镜手术围手术期出血防治专家共识

中国医疗保健国际交流促进会 · 2021-06-15

新型冠状病毒感染肺炎背景下泌尿外科诊疗防控工作建议

中国泌尿外科相关专家组（统称） · 2020-02-25

泌尿外科手术部位感染预防中国专家共识(2019版)

中国泌尿外科相关专家组（统称） · 2019-06-30

2015 CUA指南：泌尿外科手术预防性应用抗生素

加拿大泌尿外科协会(CUA,Canadian Urological Association) · 2015-01-22

拓展阅读

2018 AUA指南：良性前列腺增生引起的下尿路症状的手术管理

美国泌尿外科学会(AUA,American Urological Association) · 2018-05-15

2018 CUA指南：男性下尿路症状/良性前列腺增生(更新版)

加拿大泌尿外科协会(CUA,Canadian Urological Association) · 2018-10-12

黄莪胶囊在良性前列腺增生临床应用中国专家共识

中国中医药信息研究会(CIATCM,China Information Association For Traditional Chinese Medicine and Pharmacy) 男科分会 · 2018-10-30

2020 AUA指南：良性前列腺增生所致下尿路症状的外科治疗（修订版）

美国泌尿外科学会(AUA,American Urological Association) · 2020-07-23

良性前列腺增生加速康复护理中国专家共识

中华医学会男科学分会 · 2021-07-30

2021 AUA指南：良性前列腺增生所致下尿路症状的管理-第Ⅱ部分：手术评估和治疗

美国泌尿外科学会(AUA,American Urological Association) · 2021-08-13